Ashurst Advised ICG on Strategic Investment in Alfa Medicus in Singapore
Ashurst, a global law firm, advised Intermediate Capital Group (ICG), a leading LSE-listed alternative asset manager, on
Ashurst Advised ICG on Strategic Investment in Alfa Medicus in Singapore Ashurst, a global law firm, advised Intermediate Capital Group (ICG), a leading LSE-listed alternative asset manager, on its investment in Alfa Medicus Pte. Ltd. (the Company). ICG partnered with Dr. Lim Beng Hai, the Company’s founder, and a consortium of healthcare professionals in this transaction. Alfa Medicus,...
Ashurst Advised ICG on Strategic Investment in Alfa Medicus in Singapore
Ashurst, a global law firm, advised Intermediate Capital Group (ICG), a leading LSE-listed alternative asset manager, on its investment in Alfa Medicus Pte. Ltd. (the Company). ICG partnered with Dr. Lim Beng Hai, the Company’s founder, and a consortium of healthcare professionals in this transaction.
Alfa Medicus, a leading private day surgery provider in Singapore, offers a comprehensive healthcare platform that includes day surgery centres, diagnostic imaging services, and specialist clinics.
Alfa Medicus used the funds from ICG’s investment to acquire 14 healthcare companies, including Novena Surgery, Aptus Surgery, Novaptus Surgery, OHM, and CHARMS.
“We are pleased to support ICG, a key client of our firm, in this significant investment in Asia’s healthcare landscape,” Ashurst’s Southeast Asia head of M&A Tao Koon Chiam stated.
The transaction was overseen by Ashurst ADTLaw Director Tao Koon Chiam, with support from fellow Ashurst ADTLaw Director Xiaozheng Ko, along with Stefanie Loh and Charissa Loi.